IDEAYA Biosciences posted a net loss of $112.45 million, widening from $98.54 million in the prior quarter; loss per share deepened to $1.22 from $1.11.
Collaboration revenue rose 35.02% from the prior quarter to $8.86 million.
Research and development expenses increased to $108.69 million from $95.73 million.
Cash position and pipeline updates
Cash, cash equivalents, and marketable securities climbed to $1.24 billion at June 30 from $972.9 million at March 31, following $323.4 million in net offering proceeds.
The OptimUM-02 trial of darovasertib plus crizotinib in metastatic uveal melanoma met its primary endpoint; NDA filing is underway with completion expected in H2 2026.
Management said the company is discussing an IDE849 Phase 3 registrational trial with the FDA, targeting initiation by end-2026; cash runway guidance into 2030 remains unchanged.
IDYA•
